Is IncobotulinumtoxinA safe while breastfeeding?
Here is what LactMed, the Drugs and Lactation Database published by the U.S. National Institute of Child Health and Human Development (NICHD), reports about IncobotulinumtoxinA. The text below is quoted from that source — it is not our own verdict.
Summary of use during breastfeeding
No data exist on the medical use of incobotulinumtoxinA during breastfeeding. However, it is not detectable systemically after intramuscular use, thus excretion into breast milk is considered unlikely. The closely related drug, onabotulinumtoxinA was not detectable in the milk of two women and detectable in only minute amounts in 5 others after 40 to 92 units injected into the face. Many mothers have breastfed their infants after injection of onabotulinumtoxinA for migraine.[1] An international guideline considers onabotulinumtoxinA acceptable in breastfeeding women with chronic migraine.[2] No special precautions are required.
Effects on the breastfed infant
Published information on the medical use of incobotulinumtoxinA during breastfeeding was not found as of the revision date.
One mother breastfed her infant while she was experiencing toxicity from botulism poisoning. She breastfed her 2-month-old infant. Although the mother died, the infant had no symptoms.[6]
A woman developed botulism after ingesting fermented salmon eggs while breastfeeding her 8-month-old breastfed (extent not stated) infant. The infant developed no signs or symptoms of botulism even though she continued to nurse throughout the mother's hospitalization.[3]
Effects on milk supply
Relevant published information was not found as of the revision date.
Levels in milk
Maternal Levels. Published information on the medical use of incobotulinumtoxinA during breastfeeding was not found as of the revision date.
Type A botulinum toxin was detected in the blood and stools of a nursing mother after ingesting fermented salmon eggs. She was given 2 vials of trivalent botulism antitoxin, 1 intravenously and 1 intramuscularly. A milk sample obtained 3 days after the onset of her illness and 4 hours after administration of botulinum antitoxin had no detectable botulinum toxin nor botulism organisms.[3]
Four women undergoing cosmetic procedures were injected with doses ranging from 40 to 92 units of onabotulinumtoxinA. Milk samples were taken at baseline and 1, 3 and 5 hours after the injections. Two women had undetectable (<46 ng/L) levels in all samples after receiving 54 and 92 units. Two other women who received 40 and 46 units had peak milk levels of 422 ng/L and 747 ng/L, respectively.[4]
In a preprint, 3 women were reported who received onabotulinumtoxinA at 3 sites for facial cosmetic procedures for a total dose of 64 units. They were instructed to express 200 mL of breastmilk before treatment and 1, 6, 24, 36, 48, and 72 hours after treatment using a manual pump. In addition, milk samples were collected at 5, 6, 7, 10, and 11 days, 2 months, 4 months, and 5 months after the injections. The highest observed concentration was 33.4 ng/L in in one woman 4 days after the injection. In another woman, the highest concentration occurred 3 days after the injection. After the first week, milk concentrations in one woman decreased to a low of 6.9 ng/L at 11 days, before another peak of 26.6 ng/L at 2 months after the injections. If the highest concentration and a dose of 150 mL/kg daily breastmilk intake are used, a breastfed infant would receive a maximum of 5 ng/kg of botulinum toxin A orally per day, which is far below the dose of 12 to 25 units/kg given by injection to children with spastic cerebral palsy.[5]
Infant Levels. Type A botulinum toxin was detected in the blood and stools of a nursing mother after ingesting fermented salmon eggs. No botulinum toxin was detected in the breastfed infant's blood or stool on the day the mother was admitted to the hospital (3 days after the onset of illness) and no botulism organisms were detected in the infant's stools.[3]
Source: Drugs and Lactation Database (LactMed), National Institute of Child Health and Human Development (NICHD), via NCBI Bookshelf, record “IncobotulinumtoxinA” (LM1481). LactMed on NCBI Bookshelf. LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Educational summary of an authoritative source — not medical advice. Never start, stop, or change a medicine while breastfeeding without confirming with your doctor.
